Dr. Karl Aoun (PhD) joined the University of New South Wales as a Clinical Research Coordinator at the National Drug and Alcohol Research Centre, in August 2020. He is currently working on the Quit Smoking Study investigating the effectiveness, cost-effectiveness and safety of Vaporised Nicotine Products in comparison with Nicotine Replacement Therapy, in Australian low-SES populations of current daily smokers.
Karl completed his PhD (Medicine) at The University of Sydney in 2020. His work explored the anatomical, neuro-chemical and functional attributes of the pre-clinical ultrasound risk marker for Parkinson’s disease in the healthy adult population, with the aim to increase understanding of changes that may occur in the earliest pre-clinical stages of Parkinson’s disease and support the development of methods to better identify this disease stage during life.
ORCID ID: https://orcid.org/0000-0003-1963-9288
Doctor of Philosophy (Medicine)
Tsartsalis S; Toumier BB; Aoun K; Habiby S; Pandolfo D; Dimiziani A; Ginovart N; Millet P, 2017, 'A single-scan protocol for absolute D-2/3 receptor quantification with [I-123]IBZM SPECT', NEUROIMAGE, vol. 147, pp. 461 - 472, http://dx.doi.org/10.1016/j.neuroimage.2016.12.050